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Abstract 
Introduction: Management of osteoarthritis (OA) includes the use of non-pharmacological and 
pharmacological therapies. Although walking is commonly recommended for reducing pain and 
increasing physical function in people with OA, glucosamine sulphate has also been used to 
alleviate pain and slow the progression of OA. This study evaluated the effects of a progressive 
walking program and glucosamine sulphate intake on OA symptoms and physical activity 
participation in people with mild to moderate hip or knee OA. 
 
Methods: Thirty-six low active participants (aged 42 to 73 years) were provided with 1500 mg 
glucosamine sulphate per day for 6 weeks, after which they began a 12-week progressive 
walking program, while continuing to take glucosamine. They were randomized to walk 3 or 5 
days per week and given a pedometer to monitor step counts. For both groups, step level of 
walking was gradually increased to 3000 steps/day during the first 6 weeks of walking, and to 
6000 steps/day for the next 6 weeks. Primary outcomes included physical activity levels, 
physical function (self-paced step test), and the WOMAC Osteoarthritis Index for pain, stiffness 
and physical function. Assessments were conducted at baseline and at 6-, 12-, 18-, and 24-week 
follow-ups. The Mann Whitney Test was used to examine differences in outcome measures 
between groups at each assessment, and the Wilcoxon Signed Ranks Test was used to examine 
differences in outcome measures between assessments. 
 
Results: During the first 6 weeks of the study (glucosamine supplementation only), physical 
activity levels, physical function, and total WOMAC scores improved (P<0.05). Between the 
start of the walking program (Week 6) and the final follow-up (Week 24), further improvements 
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were seen in these outcomes (P<0.05) although most improvements were seen between Weeks 6 
and 12. No significant differences were found between walking groups. 
 
Conclusions: In people with hip or knee OA, walking a minimum of 3000 steps (~30 minutes), 
at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms. A 
more robust study with a larger sample is needed to support these preliminary findings.  
 
Trial Registration: Australian Clinical Trials Registry ACTRN012607000159459. 
 
© 2010 Ng et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
 
Introduction {1st Level Heading} 
Osteoarthritis (OA) is the most common musculoskeletal disorder and the leading cause of pain 
and disability in the USA and Australia [1,2]. In Australia, it affects 7.8% of the population, and 
projections indicate that the prevalence will increase to 9.8% by 2020 [3]. 
There is no known cure for OA. The goal of treatment, therefore, is to help reduce patients’ pain, 
prevent reductions in their functional ability and maintain or increase their joint mobility. For 
individuals with moderate symptoms of OA and no other health problems, international 
guidelines for initial treatment recommend non-pharmacological treatments, including lifestyle 
changes [4-9]. A number of non-pharmacological treatments have been studied for the 
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management of OA, but because there have been few well-conducted studies, the effectiveness 
of most non-pharmacological treatments is open to question [10].  
Exercise, however, as a treatment for OA has been studied in numerous randomised controlled 
trials, mostly in people with OA of the knee. Most of these have focused on improving the 
stability of joints, range of movement and aerobic fitness in order to decrease patients’ pain and 
disability [11]. Patients with mild to moderate symptoms of knee or hip OA who have 
participated in aerobic exercise programs have experienced increases in aerobic capacity [11,12] 
and functional ability [13,14], and decreases in pain, fatigue, depression and anxiety [11-13,15]. 
These results have led to recommendations for the use of aerobic exercise for the treatment of 
OA [4,7-9].  
A recent review of randomised controlled trials in patients with knee OA found three types of 
exercise program (supervised individual, supervised group-based and unsupervised home-based) 
have been evaluated, with decreases in pain and physical function not differing significantly 
among participants in the three types [13]. In contrast to pharmacological treatments, which can 
cause gastrointestinal side effects [16], moderate-intensity aerobic exercises are well tolerated 
over the long term and have similar effects (effect size [ES] = 0.52) [17] for reducing pain to 
those seen with paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs; ES = 0.32) 
[18]. Compared with supervised programs, home-based programs are more convenient for 
participants, feasible in community settings and cost-effective for large populations, suggesting 
their suitability as a public health approach [13]. 
Walking may be an appropriate activity for home-based programs [19], because it has resulted in 
greater improvements in pain and greater participation rates than other forms of aerobic exercise, 
such as running or cycling [20]. In studies assessing the effectiveness of walking for patients 
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with knee OA, moderate improvements in pain (ES = 0.52) and physical functioning (ES = 0.32) 
have been found [17] without adverse effects on OA symptoms [14]. The Physical Activity 
Guidelines Advisory Committee recommends that individuals with OA engage in moderate-
intensity, low-impact activities such as walking, three to five times per week for 30 to 60 minutes 
per session [21]. 
Despite the accumulating international evidence suggesting that aerobic exercise is effective in 
reducing symptoms of OA of the knee, and to a lesser degree of the hip, an important question 
remains: What is the appropriate ‘dose’ of exercise (intensity, frequency, and duration) for 
significant improvements in symptoms of knee and hip OA? More broadly, the question of an 
appropriate dose of exercise has yet to be determined for people with arthritis in general [21]. In 
previous studies, exercise format, duration, intensity, and type of exercise varied widely, making 
it difficult to specify the required dose for optimal benefits. Even among the studies that used 
walking, programs have varied in content, duration of sessions and length of the intervention 
[17]. Only one small study [22] has examined the dose issue, and it focused on intensity of 
exercise. The researchers found that higher and lower intensity exercises are equally effective in 
improving symptoms of OA.  
One treatment that is used in combination with or without exercise by some people with early hip 
or knee OA is glucosamine sulphate (GS), a natural occurring substance believed to assist with 
building and repair of cartilage. It is taken as a complementary medicine that is safe and has few 
side effects [8]. Two recent randomised trials from Europe have shown that GS slows 
radiological progression of knee OA [23,24]. In a meta-analysis of 20 double-blind randomised 
control trials, glucosamine was reported to improve well-being and to be as safe as placebo [25]. 
Although results of a review further suggest glucosamine offers moderate improvements in well-
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being [26], some trials reported little or non-significant effects of glucosamine when compared 
with placebo [27,28]. These conflicting results could be due to differences in the type of 
preparation used (GS or glucosamine hydrochloride), dose or bioavailability of the glucosamine 
preparation used.  
Although some individuals with OA are using both glucosamine and exercise to relieve 
symptoms, no study has examined the effectiveness of the combined effects of exercise and GS 
on relieving symptoms of hip and knee OA. The main aim of this feasibility study was to 
evaluate the combined effects of a progressive walking program and GS intake on symptoms of 
OA and physical activity participation in people with hip or knee OA. Secondary aims were to 
compare the effectiveness of two frequencies of walking (three and five days per week) and three 
step levels (1500, 3000 and 6000 steps per day) of walking, combined with GS intake, and to 
examine compliance with GS intake and the walking program.  
 
Materials and methods {1st Level Heading} 
Participants {2nd Level Heading} 
Adults with hip or knee OA were recruited in Brisbane, Australia, from flyers posted at 
community sites and in doctors’ offices, newspaper and newsletter advertisements, and segments 
on local television and radio programs. Eligibility criteria were: aged 40 to 75 years; having 
physician-diagnosed OA in at least one hip or knee (verified by a doctor’s letter confirming 
diagnosis); experiencing pain, stiffness, crepitus and difficulty with daily activities within the 
previous month; an ability to walk at least 15 minutes continuously; and an ability to safely 
participate in moderate-intensity exercise, as determined by the Sports Medicine Australia Stage 
I pre-exercise screening questions [29]. Individuals were excluded if they: had other forms of 
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arthritis; had corticosteroid or viscosupplement injections within the previous three months; had 
a history of infection in a knee or hip; were living in a dependent environment; were taking daily 
medication for OA, including analgesia; or were allergic to shellfish. Individuals who were 
planning to have surgery in the next six months, receiving psychiatric or psychological 
treatment, pregnant or planning to become pregnant, exercising more than 60 minutes per week, 
or participating in another research study were also excluded.  
 
Study design {2nd Level Heading} 
The study design is shown in Figure 1. This was a 24-week feasibility study with participants 
randomised to one of two intervention groups. Written informed consent was required at the 
baseline assessment, before participation could begin. Participants went through a two-week run-
in, washout period before the first assessment. For this period and the rest of the study period, 
participants were informed to discontinue all over-the-counter or prescription medications for 
their OA symptoms. However, they were told that they could take their choice of rescue 
analgesia as needed for pain or swelling during the study period.  
Before the first assessment, the data collector (author NTMN) used a computer random number 
generator to allocate participants to one of two groups. Participants were told of their group 
allocation at the baseline assessment. For practical reasons, allocation to group was not 
concealed. All participants received six-week supplies of GS at baseline, Week 6 and Week 12. 
At Week 6, participants began a 12-week progressive walking program called Stepping Out, 
either walking three or five days per week, depending on group assignment. The walking 
program ended at Week 18. The next six weeks constituted a follow-up period to test whether the 
intervention effects persisted after intervention completion. Study measures were administered 
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during one-on-one interviews with participants at baseline and 6-, 12-, 18-, and 24-weeks after 
baseline. Assessments were conducted at the University of Queensland or at the participant’s 
home. The study protocol was approved by the University of Queensland Medical Research 
Ethics Committee. 
 
Main outcome measures {3rd Level Heading} 
Physical activity {4th Level Heading} 
Time spent in physical activities was measured using a print version of the Active Australia 
physical activity questions [30], which have been shown to have acceptable reliability and 
validity [31]. A comparison of activity classification (i.e. ‘active,’ ‘insufficiently active,’ 
‘sedentary’) showed moderate agreement between two testing occasions, 24 hours apart (Kappa 
coefficient = 0.50), a finding similar to those observed for other physical activity questionnaires 
used internationally [32]. Walking (to and from places and for exercise), leisure-time moderate-
intensity physical activities, and vigorous-intensity physical activities were assessed separately. 
Minutes per week spent in each of these activities was summed to create a total physical activity 
score.  
 
Osteoarthritis symptoms {4th Level Heading} 
The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS (numeric 
rating scale) [AU: Please define] 3.1 was used to measure pain, stiffness and physical function 
[33]. The index has been extensively validated and widely used in studies of knee and hip OA 
[34,35]. The index consists of three subscales with a total of 24 items (5 pain, 2 stiffness and 17 
physical function) with test-retest reliability estimates of 0.68, 0.68 and 0.72 for the pain, 
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stiffness, and physical function subscales, respectively [34,35]. Participants placed an ‘x’ on a 
numerical (visual analogue) scale ranging from 0 to 10. For the pain subscale, response options 
ranged from no pain to extreme pain; for the stiffness subscale, from no stiffness to extreme 
stiffness; and for the physical function subscale, from no difficulty to extreme difficulty. 
Responses to items on each of the three subscales were summed to create subscale scores. A total 
scale score (range 0 to 240) was calculated by simple summation of these subscale scores with 
higher scores indicating more severe symptoms.  
Physical function was also assessed objectively with the Self-Paced Step Test (SPS) [36]. This 
test was selected because it could be used in participants’ homes: it was portable, practical for 
use with minimal space and suitable for use in individuals with OA. Participants were asked to 
step up and down two 20 cm steps, 20 times at a comfortable pace. Time taken to complete the 
test was recorded to the nearest second with a digital stopwatch. A higher score indicated lower 
physical function. Immediately after the SPS test, the WOMAC pain subscale was re-
administered to assess the level of pain after an activity that involved movement of the hip and 
knee joints.  
 
Secondary outcome measures {3rd Level Heading} 
Correlates of physical activity {4th Level Heading} 
Five theoretical constructs that were addressed in the Stepping Out program were measured with 
questionnaires. The Arthritis Self-Efficacy Scale assessed confidence of affecting change for 
managing arthritis pain, function and other symptoms, with higher scores indicating greater 
efficacy for managing symptoms [37]. One study has demonstrated adequate internal consistency 
for the scale’s pain (Cronbach alpha = 0.76), function (Cronbach alpha = 0.89) and other 
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symptoms (Cronbach alpha = 0.87) subscales [37]. The Self-Regulation Scale assessed the use of 
self-monitoring and goal setting strategies for physical activity behaviour with higher scores 
representing higher self-efficacy in meeting physical activity goals. Higher self-regulation scores 
have been associated with engaging in more moderate and vigorous physical activities (r = 0.50) 
[38]. The Self-Efficacy for Physical Activity Scale evaluated confidence in ability to participate 
regularly in physical activities, with higher scores indicating greater self-efficacy for physical 
activity. A high test-retest reliability estimate (r = 0.90) has been reported for this scale [39]. The 
Benefits of Physical Activity Scale determined whether participants were aware of the benefits 
of physical activity, and the Barriers to Physical Activity Scale identified factors that made 
participation in physical activities difficult [40]. Higher scores on the Benefits of Physical 
Activity Scale indicated a perception of more benefits, and a high test-retest reliability (r = 0.85) 
has been reported for this scale [40]. Higher scores on the Barriers to Physical Activity Scale 
indicated a perception of more barriers to physical activity. Barrier scale scores have been 
significantly and inversely correlated with exercise (r = -0.22) [40]. 
 
Health outcomes {3rd Level Heading} 
The Goldberg Anxiety and Depression Scale [41] was used to measure symptoms of anxiety and 
depression. Nine items measured anxiety, and an additional nine measured depression, with 
response options of ‘Yes’ and ‘No’. The summary score was calculated by adding the total 
number of ‘Yes’ responses to the 18 items. With a range of 0 to 18 on the scale, a higher score 
indicated more symptoms of anxiety and depression. The anxiety and depression subscales have 
sensitivities of 82% and 85%, respectively. 
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Body weight was measured to the nearest 0.5 kg using calibrated portable scales (SECA, [AU: 
Add the name of the town] Hamburg, Germany). 
 
Demographic characteristics {3rd Level Heading} 
Data on age, country of birth (a measure of race/ethnicity), marital status, living arrangements, 
caring responsibilities, education and employment status were collected using a self-report 
survey.  
 
The intervention {2nd Level Heading} 
Starting at baseline, participants were supplied with GS (Bio-OrganicsTM Glucosamine Sulphate 
Complex 1000, Virginia, Queensland, Australia [AU: Add location]) and asked to take two 
capsules (750 mg each) daily. The Stepping Out program commenced at Week 6. It was 
developed to influence self-efficacy (confidence in one’s ability to be physically active) and 
other constructs from Social Cognitive Theory that were hypothesised to impact self-efficacy 
[42]. This theory has been found to be effective as a framework for previous interventions in 
which OA sufferers managed their OA with exercise [43-48]. 
The Stepping Out program included: a walking guide; a pedometer; weekly log sheets for 
recording daily step counts, GS intake and intake of other medications and supplements; and a 
weekly planner for scheduling walking sessions (Table 1). Participants were encouraged to use 
strategies from the Stepping Out walking guide, to increase their self-efficacy towards walking. 
Strategies included behavioural contracting (using a written contract to meet the study 
requirements), goal setting, planning for walking sessions, and obtaining social support for 
walking. The interventionists also brainstormed with participants ways to increase their walking, 
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make their walks enjoyable and overcome barriers to walking. This interaction with the 
interventionist lasted approximately one hour. Details of the content of each strategy can be 
found in Table 1. All participants received the same materials and instructions, but participants in 
the three-day walking group were asked to walk three days per week and participants in the five-
day walking group were asked to walk five days per week. 
Participants received the program materials and instructions for following the program and 
wearing the pedometer after the assessment portion of the Week 6 session. The first author 
(NTMN, a doctoral student with training in exercise science and physical activity behaviour 
change) served as both data collector and interventionist. At that session, participants were asked 
to initially walk at least 1500 steps (approximately 15 minutes) on each ‘walking’ day in addition 
to any walking they were currently doing, and to do this additional walking in a single session. 
They were asked to increase from 1500 steps to 3000 steps (approximately 30 minutes) by the 
Week 12 assessment and, to accommodate participants who were unable to walk this amount 
continuously, were advised that the walks could be done in bouts of at least 1500 steps each. 
They were also advised to increase their step counts at a rate that was comfortable for them. At 
the Week 12 session, participants were asked to increase their walking to 6000 steps 
(approximately 60 minutes) by Week 18, the end of the intervention. At the Week 18 session, 
they were advised to either continue with the walking program or to try other physical activities 
of their choice for the last six weeks of the study, the follow-up period.  
 
Statistical analysis {2nd Level Heading} 
Study completers were compared with those who dropped out of the study, using demographic 
and outcome variables measured at baseline. Likewise, the three-day and five-day walking 
 13
groups were compared at baseline. Categorical variables were examined using the chi-squared 
test for independence, and continuous variables were examined with the Mann Whitney test, 
because the data were not normally distributed. For the Mann Whitney test, differences in the 
ranked positions of scores in different groups are compared [49].  
Compliance with the study protocol’s recommendation for GS intake, for the number of 
‘walking’ days per week, and for the number of steps to walk each ‘walking day’ were computed 
using data collected from weekly log sheets. For each week between baseline and Week 18, GS 
compliance was defined as the proportion of participants who recorded taking two GS capsules 
per day at least five days of the week. For each week between Weeks 6 and 18, compliance with 
the number of walking days was defined as the proportion of participant who reported walking 
the prescribed number of days (three for the three-day walking group; five for the five-day 
walking group). Compliance with the number of steps prescribed for each walking day was 
defined as the proportion of participants who reported walking 1500 steps at Week 7 (after the 
first week of walking), 3000 steps at Week 12 and 6000 steps at Week 18. Chi-squared test for 
independence was used to compare groups on the proportion of participants who complied with 
the recommendation for GS intake each week. Independent samples t-tests were used to compare 
groups on the mean number of days walked during each of the 12 weeks of the Stepping Out 
program and on the mean number of steps walked per ‘walking’ day during that time. Type and 
usage of rescue analgesia were also collected from weekly log sheets, and median number of 
days that these medications were used over the intervention period was computed.  
The Mann Whitney test was used to examine differences between the three-day and five-day 
walking groups at Weeks 6, 12, 18 and 24 for the main outcome variables, physical activity and 
OA symptoms. The remaining analyses were then analysed separately by group, only if group 
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differences were found. Otherwise, data from the two groups were pooled for analysis of 
intervention effects. Differences between assessment weeks in scores on all outcome variables 
were examined using the Wilcoxon Signed Ranks Test. An effect size (r; z-score divided by the 
square root of the sample size) was computed for each statistically significant finding [49], and 
Cohen’s d benchmark was used to determine the magnitude of the effect, with 0.20 representing 
small, 0.50 representing moderate and 0.80 representing large effect sizes [50]. Confidence 
intervals for the effect sizes were not calculated because data were not normally distributed. 
Instead, inter-quartile ranges of the raw scores were computed. Given that this was a feasibility 
study, data were analysed on a per protocol basis, meaning that participants who did not 
complete all study assessments were excluded. For study completers, missing data were replaced 
by the mean of the preceding and proceeding values [51]. Statistical significance was set at a 
two-tailed alpha level of 0.05 for all analyses. 
 
Results {1st Level Heading} 
Participants {2nd Level Heading} 
Over 16 weeks of recruitment, 536 people expressed interest in the study (Figure 2). The 
preliminary screening revealed that 48% had physician-diagnosed OA in a knee or hip. Of these, 
14% met all eligibility criteria, gave written informed consent and were enrolled into the study. 
Of those who met the eligibility criteria, 47% (n = 17) were randomised to the five-day walking 
group and 53% (n = 19) to the three-day walking group. Of the participants who enrolled, 77% 
completed the study (three-day group: n = 13, five-day group: n = 15). Three participants 
dropped out during the first six weeks of the study, before the walking program began. Reasons 
were a death in the family (n = 1), a physician’s advice to withdraw due to potential impact of 
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walking on OA (n = 1) and a physician’s advice to withdraw due to potential impact of walking 
on other health conditions (n = 1). Five additional participants dropped out during the walking 
program. Reasons for drop-out from the three-day walking group were a death in the family (n = 
1; dropout in Week 8), pain in the knees (n = 1; Week 7) and a torn Achilles tendon (n = 1; Week 
7), and from the five-day walking groups were pain while walking due to leg length 
discrepancies (n = 1; Week 12) and development of Bakers’ Cyst causing pain while walking (n 
= 1; Week 9). None of these conditions was directly attributable to participation in the program. 
No differences were found between study completers and those who dropped out on any study 
variable.  
Demographic characteristics of study completers are presented in Table 2. Intervention groups 
did not differ significantly on any of the variables examined.  
 
Compliance {2nd Level Heading} 
From baseline to Week 18, 100% of three-day group participants were compliant with taking the 
weekly GS supplementation for all but three weeks, and 100% of five-day group participants 
were compliant with taking the weekly GS supplementation for all but two weeks. For weeks in 
which compliance was not 100%, compliance was 90% or more for each intervention group. No 
differences were found between groups in the proportion who were compliant with taking the GS 
(P = 0.18). 
Nineteen of the 28 study participants (three-day group n = 7, 58%, five-day group n = 12, 80%) 
reported taking paracetamol and/or NSAIDs as rescue analgesia, with the most popular 
medications being paracetamol preparations (n = 12). Over the 18-week intervention period, 
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study participants took rescue analgesia a median of 5.5 days (25th percentile = 0 days; 75th 
percentile = 18 days).  
For each week of the Stepping Out program (Weeks 7 to 18), most participants in both groups 
were compliant with walking the number of ‘walking days’ called for in the protocol (i.e., they 
walked the prescribed three or five days per week), but compliance was higher in the three-day 
walking group than in the five-day walking group (Figure 3). Among participants in the three-
day walking group, there was 100% compliance with walking three days per week during Weeks 
8, 9, 12, 15, and 18. Among participants in the five-day walking group, compliance ranged from 
93% (Week 7) to 58% (Week 16) during the 12-week walking program. The mean number of 
days walked throughout the 12 weeks was also computed. No significant difference in number of 
days walked were found between groups although there was a trend in significance (P = 0.06). 
On average, participants in the three-day group walked three days per week (mean days/week= 
3.07 (standard deviation (SD) 0.82) days), but participants in the five-day group did not walk 
five days per week (mean days/week= 3.93 (SD 1.09) days).  
Another measure of compliance was the proportion of participants in each group who complied 
with the number of steps indicated in the study protocol. In the first week of the walking program 
(Week 7), 89% of participants in the three-day group and 93% in the five-day group complied 
with walking at least 1500 steps on each walking day. These percentages decreased to 75% in the 
three-day group and 79% in the five-day group by Week 12 when the target step level increased 
to 3000 steps. By Week 18, when the target step level increased to 6000 steps, the percentages 
were 83% and 50% in the three- and five-day groups, respectively. Participants in both groups 
increased the number of steps they walked each ‘walking’ day over the weeks of the Stepping 
Out program, and no significant group differences in steps per ‘walking’ day were seen. For the 
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two groups combined, the mean number of steps walked per ‘walking’ day for the study 
increased from 3920 (SD 2441) per day during the first week of the walking program (Week 7) 
to 6683 (SD 3403) per day during the final week of the program (Week 18).  
 
Differences between groups {2nd Level Heading} 
No significant differences were found between groups for the main outcome variables at any 
assessment week. Therefore, data from both groups were combined for the rest of the analyses. 
The only missing data were for weight and body mass index (BMI) for one person in Week 12, 
and for weight and BMI (n = 2), blood pressure (n = 2), post-SPS WOMAC pain (n = 3) and SPS 
(n = 3) at Week 18. Changes in outcome variables between Week 6 and Week 24 are shown in 
Tables 3 and 4. Changes from baseline to Week 6 (GS supplementation only) and from Week 6 
to Week 24 (onset of walking program to end of follow-up) are described below. We chose to 
focus on Weeks 6 to 24 because, from a public health point of view, it is important to ascertain 
whether any effects are maintained after the end of the program. 
 
Changes between baseline and Week 6 (GS supplementation only) {2nd Level Heading} 
Although instructed not to increase their physical activity, from baseline to the Week 6 
assessment, participants significantly increased their median weekly minutes of physical activity 
(Table 3). There were also significant improvements (decreases) in SPS times and WOMAC 
stiffness and physical function scores although WOMAC pain scores did not change significantly 
(Table 3). Scores on the Arthritis Self-Efficacy Scale pain and ‘other symptom’ subscales and on 
the Barriers to Physical Activity Scale also improved significantly (Table 4). 
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Changes between Week 6 and Week 24 {2nd Level Heading} 
Between the start of the walking program (Week 6) and the end of the follow-up period (Week 
24), there were significant improvements in participants’ weekly median minutes of physical 
activity, in SPS test times and in all WOMAC scores except stiffness scores (Table 3). However, 
there was a trend for improvement in stiffness (P = 0.06). Significant improvements were also 
seen in self-efficacy towards managing arthritis pain and ‘other symptoms’, in physical activity 
self-regulation, and in the number of perceived barriers to physical activity (Table 4). There were 
also trends for improvements in self-efficacy towards managing arthritis-related functioning (P = 
0.06), in self-efficacy towards physical activity (P = 0.07) and in symptoms of anxiety and 
depression (P = 0.08).  
 
Discussion {1st Level Heading} 
The main aims of this feasibility study were to evaluate the combined effects of a progressive 
walking program and GS intake on symptoms of OA and on physical activity participation in 
people with hip and knee OA, and to compare the effectiveness of two frequencies (three and 
five days per week) and three steps levels (1500, 3000 and 6000 steps) of walking. Thirty-six 
participants were given GS for 18 weeks of the study. After the first six weeks, they began the 
12-week graduated Stepping Out walking program and were randomised to walk three or five 
days per week.  
For the first six weeks, before the introduction of Stepping Out, daily GS supplementation was 
found to be effective in alleviating symptoms of hip and knee OA. Stiffness and physical 
function, both measured with WOMAC subscales, improved significantly (median scores 
improved by 30% and 9%, respectively) although pain, also measured with the WOMAC, did 
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not. Objectively-measured physical function also improved significantly, by 13%. It is possible 
that these changes were due to increases in physical activity in this period, even though 
participants were asked to not change their physical activity during this time. The improvements 
partially support those from previous randomised controlled trials. In these trials [23,24,52], 
improvements were significantly greater for the groups assigned to receive GS than for the 
groups assigned to receive placebos or alternative therapies. In a three-year trial, Reginster and 
colleagues [24] found that among patients with knee OA, WOMAC index scores improved 24% 
with daily GS supplementation and WOMAC physical function scores improved by 22%. Scores 
on the WOMAC pain scale also improved, by 19%. In a three-year trial by Pavelka and 
colleagues [23], patients with knee OA who took GS experienced improvements in pain and 
physical function of 20 to 25%. In a six-month trial [52], patients with knee OA who were 
assigned to a GS group had improvements in WOMAC index scores of 12% and physical 
function scores of 13%. In other trials [27,28,53], however, no significant improvements with 
glucosamine supplementation were found. Differences in findings between studies can be 
explained in part by the participant characteristics of each sample. In the studies that found no 
improvements, participants tended to have mild symptoms of OA at baseline. In the current study 
and in other studies that found significant improvements with GS, participants tended to have 
moderate to moderately-high levels of symptoms (i.e., median scores above the median point in 
the scale) at baseline. Other differences between studies include the GS preparation used. The 
bioavailability of GS products can affect the rate that the ingested GS reaches the target tissue to 
evoke metabolic changes in the articular cartilage [53]. This is the first time that the benefits of 
GS have been shown in a relatively short six-week period. 
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The major finding of the current study was that being encouraged to walk five days a week was 
not more effective than being encouraged to walk three days, in terms of increasing time spent in 
physical activities, reducing pain and stiffness, increasing physical function, and improving most 
other measures used in the study. These findings are not surprising given that at each follow up 
the three-day and five-day walking groups did not differ significantly in the mean number of 
days actually walked per week, the mean number of daily steps walked on each walking day as 
measured with a pedometer or their weekly minutes of physical activity as measured by 
questionnaire. On average, participants in the three-day walking group walked three days per 
week and participants in the five-day walking group walked slightly less than four days per 
week, suggesting that it may be difficult to get people with hip or knee OA to walk more than 
three to four days per week. Another important finding was that increasing the number of steps 
per walking day from 1500 to 3000 steps per day, in conjunction with GS intake, resulted in a 
125% increase in minutes of physical activity, a 17% reduction in pain scores, and improvements 
in physical function measured subjectively using the WOMAC (a 37% reduction in scores) and 
objectively using the SPS test (a 12% decrease in time). When the walking step level was 
increased from 3000 to 6000 steps a day, the primary changes were a 57% increase in physical 
activity participation and an 8% improvement in objectively-measured physical function. During 
the six-week follow up, minutes per week of physical activity decreased 46%, but physical 
function, measured objectively, continued to improve significantly, by 5%. These results suggest 
that increasing walking by 3000 steps (about 30 minutes) on at least three days per week can 
significantly reduce pain and increase physical function in people with hip or knee OA and that 
increasing walking from 3000 steps to 6000 steps on each walking day may offer additional 
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significant improvements in physical function only. In short, more benefit comes from increasing 
walking by 3000 than from increasing walking by another 3000 steps to 6000 steps.  
The improvements in WOMAC pain and physical function are consistent with those reported for 
randomised controlled trials [14,15,44,54,55]. Kovar and colleagues [14] examined the 
effectiveness of an eight-week supervised walking and patient education program for 102 
participants with knee OA. Participants who received the program exhibited a significant 27% 
decrease in arthritis pain and a non-significant 39% improvement in physical function. Similar 
results were reported by Evcik and Sonel [54] for a three-month randomised controlled trial with 
90 participants with knee OA. Participants in a walking group had significant improvements 
ranging from 51% to 55% on the WOMAC pain subscale and of 57% on the WOMAC physical 
function subscale, compared with controls. In the most recent study, 34 older adults with knee 
OA were randomised to receive a pedometer-based walking program with arthritis self-
management education or the education only [55]. Participants who received the walking 
program had an improvement of 10% in pain while the education-only participants reported no 
improvement in pain. Differences between groups were not statistically significant, possibly due 
to a lack of power to detect differences because of the small sample size.  
Differences in effects among studies are likely to be due to differences in a number of factors, 
including sample size; eligibility criteria, most notably the criteria for exclusion based on 
baseline physical activity levels and on measures used to determine OA status; length of the 
intervention period; the physical activity prescription; the attention from and contact with 
intervention staff; the mode of intervention delivery; the type of ‘rescue medications’ allowed 
during the trial; and the choice of outcome measures. Compared with other studies, the current 
study was short (18 weeks) and included a small sample. However, it was a feasibility designed 
 22
to inform a larger study. In previous studies, protocols ranged from supervised exercise in a 
hospital [14] to unsupervised exercise with weekly phone calls [54]. Some included both 
supervised and unsupervised exercise [15]. Some studies prescribed a mix of aerobic and 
strength training exercises [15,56,57], and others prescribed just aerobic activity [22,55]. In the 
current study, the exercise program was unsupervised walking and contact time with the 
participants was minimal, in order to test the effectiveness of a program that could be widely 
disseminated. Another difference was that in the current study, strict eligibility criteria were used 
to guarantee that only OA sufferers most in need of a physical activity program (i.e., those who 
were engaging in no or low levels of physical activity) were included. Other studies did not have 
exclusion criteria based on physical activity [54,55]. Participants in the current study were 
allowed rescue analgesia as needed while some previous studies limited these to a maximum 
dose of 4000 mg per day of paracetamol [27,53]. The highest dosage of rescue analgesia 
recorded by participants in our study was 2000 mg per day of paracetamol, which was taken by 
63% (n = 12) of those who took rescue medications.  
 
Strengths {2nd Level Heading} 
This study was the first to look at the effectiveness of different frequencies and step levels of 
walking in combination with GS for relieving symptoms of OA. Although the study included 
only a small sample, the findings provide preliminary evidence on the number of walking steps 
needed to relieve OA symptoms and on the effects of different step levels on OA symptoms. 
Importantly, physical function was assessed with the SPS test, an objective measure, to verify 
any improvements found in physical function scores on the WOMAC, and walking behaviour 
was measured objectively with pedometers. Other instruments used in the study were also 
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validated measures commonly used in the physical activity field. Another strength was that 
behaviour change theory and the empirical literature were used to develop the intervention 
strategies and content. Previous studies have indicated that programs designed to impact self-
efficacy can have beneficial effects for individuals with OA [57-59], and thus strategies were 
developed to positively impact self-efficacy in this study. For example, a pedometer was 
provided as a self-monitoring and motivational tool, and monitoring step counts made it possible 
to objectively assess the amount of walking achieved by each participant. Recording the number 
of steps on weekly log sheets provided important information on participants’ progress and 
compliance with the walking program. Only one previous study [55] has used pedometers to 
increase physical activity among individuals with OA. Hence, this feasibility study can help 
inform future research examining the use of pedometers for increasing physical activity among 
individuals with knee or hip OA. Most studies have looked at older (65+ years) adults with OA, 
but this feasibility study included younger participants aged 40+ years, making the findings and 
the self-directed intervention relevant to working adults. A final strength was that the program 
was home-based and unsupervised, to accommodate the schedules, symptoms and walking 
ability of different participants. This made the program easier to integrate into individuals’ 
lifestyles than group-based activities. Anecdotally, several participants indicated that they would 
not have been able to follow the program if it had involved regular attendance at a class. 
 
Limitations {2nd Level Heading} 
The main limitation of the current study was the small sample size. Difficulties with recruitment, 
as well as loss to follow up, resulted in a small analysis sample. Some of the loss to follow up 
was attributable to pre-existing conditions that aggravated symptoms during the walking 
 24
program. However, two participants who dropped out reported that their physicians advised 
against walking. Also of note is that it is likely that a number of analyses lacked power to detect 
differences between the two walking groups. In addition, participants in the two groups reported 
walking approximately the same number of days per week and spending similar minutes per 
week in physical activities, making group differences in the other outcome measures unlikely. 
Another limitation was the use of self-report data. Although some studies use x-rays to assess 
changes in OA progression, this study was too short to expect to see changes with x-rays. 
Therefore, the primary outcome measure was the WOMAC, which has been validated and is 
widely used to examine the effects of exercise on OA symptoms [34,35]. It should also be noted 
that most previous studies measured joint space narrowing to assess the effectiveness of GS and 
exercise for OA sufferers [23,24,28]. This was not measured in the current study due to the short 
intervention period of 18 weeks. We cannot, therefore, conclude that a combination of walking 
and GS supplementation will slow down joint space narrowing, even though there was relief of 
OA symptoms. 
Given that previous research has already shown that exercise is beneficial for individuals with 
OA [60-63], the main aim of the current study was to compare the effectiveness of two walking 
programs in combination with GS, rather than to compare walking to no walking. Therefore, 
although a larger sample size would have allowed for the inclusion of a no-walking control 
group, the inclusion of such a control group was not essential to meet the main aim. Without a 
placebo control, however, the study was unable to determine the effects of GS compared with 
placebo during the first six weeks of the intervention and the effects of the walking program 
without the use of GS during the remaining weeks. Furthermore, the assessor and main analyst 
(NTMN) was not blinded to group allocation and conducted the randomisation process before 
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baseline, which may have contributed to ascertainment or performance biases. The current study 
used a per-protocol analysis but an intent-to-treat analysis should be used for a future study with 
a larger sample size. Another minor limitation was that the weather may have been a potential 
confounder. However, participants continued to walk consistently throughout the 18-week 
walking program and six-week follow up. Finally, it was not possible to obtain radiographic 
evidence from all the participants to confirm diagnosis and severity of their OA. Participants 
who were unable to provide radiographic evidence obtained a letter of diagnosis from their 
physician, but severity of the disease was not confirmed. However, from WOMAC scores 
obtained at baseline, participants were found to have, on average, moderate symptoms of knee or 
hip OA.  
 
Conclusions {1st Level Heading} 
Although the study included a small sample, the findings provide preliminary evidence that OA 
sufferers can obtain health-related benefits from the combination of GS and walking. Walking 
3000 steps per day for exercise, in bouts of at least 1500 steps each, on at least three days per 
week, provided these benefits. This amount of walking is less than current physical activity 
recommendations for the general population, but follows the recommendations for people with 
arthritis [19]. The study also provides support for the acceptability of GS in conjunction with a 
home-based walking program for people with OA, as participants were willing to comply with 
taking the glucosamine twice daily, wearing a pedometer, completing log sheets, walking three 
days per week and progressively increasing their steps per ‘walking’ day. With positive results, 
there is a need now to conduct a larger placebo-controlled trial to strengthen the findings and 
establish definitive data on the efficacy of the Stepping Out program. If the benefits of this 
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program are confirmed, it could be promoted to increase physical activity among people with hip 
or knee OA.  
 
Abbreviations {1st Level Heading} 
BMI= body mass index; ES = effect size; GS = glucosamine sulphate; NSAIDs = nonsteroidal 
anti-inflammatory drugs; OA = osteoarthritis; SD = standard deviation; SPS = self-paced step 
test; WOMAC Osteoarthritis Index = Western Ontario and McMaster Universities Osteoarthritis 
Index.  
 
Competing interests {1st Level Heading} 
All authors declare that they have no competing interests. Sanofi-Aventis Consumer Health Care 
supplied the GS for use in this study. The organisation therefore would like to see the results of 
the study published but they had no input into the study design or implementation. 
 
Authors’ contributions {1st Level Heading} 
NTMN, KCH and WJB participated in the study conception and design. NTMN participated in 
the recruitment of participants, data acquisition, implementation of the intervention and 
statistical analysis. KCH participated in the recruitment of participants, the oversight of study 
implementation and the statistical analysis. WJB participated in the oversight of study 
implementation and the statistical analysis. All authors participated in the interpretation of the 
data and the drafting of the manuscript, and all authors read and approved the final manuscript.  
 
Acknowledgements {1st Level Heading} 
 27
Funding for this research came from early career grant to Dr Heesch from The University of 
Queensland. Dr Heesch was supported by a NHMRC program grant in physical activity and 
health (Owen, Bauman, Brown, ID #301200) at the University of Queensland, School of Human 
Movement Studies. Norman Ng was supported by a University of Queensland postgraduate 
scholarship. We give a special thank you to Sanofi-Aventis Consumer Health Care for supplying 
the study with Bio-OrganicsTM Glucosamine for distribution to participants. We also would like 
to thank Prof Nick Bellamy for the use of the WOMAC Index for use in this study. We are 
grateful to participants for their participation in the study. The funders of this study had no role 
in any aspect of the study design, implementation or evaluation and did not contribute to the 
decision to submit the manuscript for publication.  
 
References {1st Level Heading} 
1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, 
Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F; National Arthritis 
Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic 
conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35. 
2. Access Economics: Painful Realities: The Economic Impact of Arthritis on Australia in 
2007. Sydney: Arthritis Australia; 2007. 
3. Access Economics: The Prevalence, Cost, and Burden of Disease of Arthritis in Australia. 
Canberra, Australia: The Arthritis Foundation of Australia; 2001. 
4.  American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. 
Recommendations for the medical management of osteoarthritis on the hip and knee. 
Arthritis Rheum 2000, 43:1905-1915. 
 28
5.  Scott DL, Shipley M, Dawson A, Edwards S, Symmons DP, Woolf AD: The clinical 
management of rheumatoid arthritis and osteoarthritis: strategies for improving 
clinical effectiveness. Br J Rheumatol 1998, 37:546-554. 
 6.  Dieppe P, Brandt KD: What is important in treating osteoarthritis? Whom should we 
treat and how should we treat them? Rheum Dis Clin N Amer 2003, 29:687-716. 
 7.  ICSI health care guidelines: diagnosis and treatment of adult degenerative joint 
diseases of the knee. [http://www.icsi.org]  
 8.  Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, 
Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, 
Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, 
Verbruggen G, Zimmerman-Gorska I, Dougados M; Standing Committee for International 
Clinical Studies Including Therapeutic Trials ESCISIT: EULAR recommendations 2003: 
an evidence based approach to the management of knee osteoarthritis. Report of a Task 
Force of the Standing Committee for International Clinical Studies Including 
Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155. 
9.  Pencharz JN, Grigoriadis E, Jansz GF, Bombardier C: A critical appraisal of clinical 
practice guidelines for the treatment of lower-limb osteoarthritis. Arthritis Res 2002, 
4:36-44. 
10. National Arthritis and Musculoskeletal Conditions Advisory Group. Evidence to Support the 
National Action Plan for Osteoarthritis, Rheumatoid Arthritis and Osteoporosis: 
Opportunities to Improve Health-Related Quality of Life and Reduce the Burden of Disease 
and Disability. Canberra, Australia: Australian Government Department of Health and 
Ageing; 2004.  
 29
11. van Baar ME, Assendelft WJ, Dekker J, Oostendorp RA, Bijlsma JW: Effectiveness of 
exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of 
randomized clinical trials. Arthritis Rheum 1999, 42:1361-1369. 
12. Minor MA, Hewett JE, Webel RR, Anderson SK, Kay DR: Efficacy of physical 
conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arthritis 
Rheum 1989, 32:1396-1405. 
13. Fransen M, McConnell S, Bell M: Exercise for osteoarthritis of the hip or knee. Cochrane 
Database Syst Rev 2001, 2. Art. No.: CD004376. 
14. Kovar PA, Allegrante JP, MacKenzie CR, Peterson MG, Gutin B, Charlson ME: Supervised 
fitness walking in patients with osteoarthritis of the knee. A randomized, controlled 
trial. Ann Intern Med 1992, 116:529-534. 
15. Ettinger WH Jr, Burns R, Messier SP, Applegate W, Rejeski WJ, Morgan T, Shumaker S, 
Berry MJ, O’Toole M, Monu J, Craven T: A randomized trial comparing aerobic exercise 
and resistance exercise with a health education program in older adults with knee 
osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA 1997, 27:25-31. 
16. Thomas J, Straus WL, Bloom BS: Over-the-counter nonsteroidal anti-inflammatory 
drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 2002, 97:2215-2219. 
17. Roddy E, Zhang W, Doherty M: Aerobic walking or strengthening exercise for 
osteoarthritis of the knee? A systematic review. Ann Rheum Dis 2005, 64:544-548. 
18. Bjordal JM, Ljunggren AE, Klovning A, Slordal S: Non-steroidal anti-inflammatory 
drugs, including cyclooxygenase-2 inhibitors, in osteoarthritis knee pain: meta-analysis 
of randomized placebo-controlled trials. Br Med J 2004, 329:1317-1320.  
19. Brosseau L, MacLeay L, Robinson V, Tugwell P, Wells G: Intensity of exercise for the 
 30
treatment of osteoarthritis. Cochrane Database Syst Rev 2003, 2. Art. No.: CD004259.  
20. Westby MD: A health professional's guide to exercise prescription for people with 
arthritis: a review of aerobic fitness activities. Arthritis Rheum 2001, 45:501-511. 
21. U.S. Department of Health and Human Services. Physical Activity Guidelines Advisory 
Committee Report. Rockville (MD): U.S. Department of Health and Human Services; 2008.  
22. Mangione KK, McCully K, Gloviak A, Lefebvre I, Hofmann M, Craik R: The effects of 
high-intensity and low-intensity cycle ergometry in older adults with knee 
osteoarthritis. J Gerontol A Biol Sci Med Sci 1999, 54:M184-M190. 
23.  Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC: Glucosamine 
sulfate use and delay of progression of knee osteoarthritis. Arch Intern Med 2002, 
162:2113-2123. 
24. Reginster JY, Deroisy R, Rovati LC, Lee RL , Lejune E, Bruyere O, Giacovelli G, Henrotin 
Y, Dacre JE, Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis 
progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256. 
25. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, 
Wells G: Glucosamine therapy for treating osteoarthritis (review). Cochrane Database 
Syst Rev 2005, 2. Art. No.: CD002946. 
26. Richy R, Bruyere O, Ethgen O, Cucherat M: Structural and symptomatic efficacy of 
glucosamine and chrondroitin in knee osteoarthritis. Ann Intern Med 2003, 163:1514-
1522. 
27.  Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham 
CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, 
Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, 
 31
Brandt KD, Moskowitz RW, Williams HJ: Glucosamine, chondroitin sulfate, and the two 
in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808. 
28.  Rozendaal RM, Koes BW, Van Osch GJ, Uitterlinden EJ, Garling EH, Willemsen SP, Ginai 
AZ, Verhaar JA, Weinans H, Bierma-Zeinstra SM: Effect of glucosamine sulfate on hip 
osteoarthritis. Ann Intern Med 2008, 148:268-277. 
29.  Sports Medicine Australia (SMA) pre-exercise screening system. 
[http://www.sma.org.au/pdfdocuments/new_pre_screening.pdf] 
30.  Australian Institute of Health and Welfare: The Active Australia Survey: A Guide and 
Manual for Implementation, Analysis and Reporting (No. CVD22). Canberra, Australia: 
Australia Institute of Health and Welfare; 2003. 
31.  Brown WJ, Burton NW, Marshall AL, Miller YD: Reliability and validity of a modified 
self-administered version of the Active Australia physical activity survey in a sample of 
mid-age women. Aust N Z J Public Health 2008, 32:535-541. 
32. Brown WJ, Trost SG, Bauman A, Mummery K, Owens, N: Test-retest reliability of four 
physical activity measures used in population surveys. J Sci Med Sport 2004, 7:205-215. 
33.  Bellamy N. WOMAC Osteoarthritis Index User Guide. Version VII. Brisbane, Australia: N. 
Bellamy; 2004. 
34. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation of WOMAC: 
a health status measure for measuring clinically important patient relevant outcomes 
following total hip or knee arthroplasty in osteoarthritis. J Ortho Rheum 1998, 1:95-108. 
35.  Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of 
WOMAC: a health status instrument for measuring clinically important patient 
 32
relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the 
hip or knee. J Rheumatol 1998, 15:1833-1840. 
36.  Petrella RJ, Koval JJ, Cunningham DA, Patterson H: A self-paced step test to predict 
aerobic fitness in older adults in the primary care clinic. J Am Geriatr Soc 2001, 49:632-
638. 
37. Lorig K, Chastain RL, Ung E, Shoor S, Holman HR: Development and evaluation of a 
scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum 1989, 
32:37-44. 
38.  Umstattd MR, Saunders R, Wilcox S, Valois RF, Dowda M: Correlates of self-regulation 
for physical activity among older adults. Am J Health Behav 2006, 30:710-719. 
39.  Marcus BH, Selby VC, Niaura RS, Rossi JS: Self-efficacy and the stages of exercise 
behavior change. Res Q Exerc Sport 1992, 63:60-66. 
40. Sallis JF, Calfas KJ, Alcaraz JE, Gehrman C, Johnson MF: Potential mediators of change 
in a physical activity promotion course for university students: Project GRAD. Ann 
Behav Med 1999, 21:149-158. 
41.  Goldberg D, Bridges K, Duncan-Jones P, Grayson D: Detecting anxiety and depression in 
general medical settings. Br Med J 1988, 297:897-899. 
42.  Bandura, A: Health promotion from the perspective of social cognitive theory. Psychol 
Health 1998, 13:623-649. 
43.  Lorig K, Gonzalez V: The integration with practices: a 12-year case study. Health Educ 
Q 1992, 19:355-368. 
 33
44.  Allengrante JP, Kovar PA, MacKenzie CR, Peterson MGE, Gutin B: A walking education 
program for the patients with osteoarthritis of the knee: theory and intervention 
strategies. Health Educ Q 1993, 20:63-81. 
45.  Keefe FJ, Kashikar-Zuck S, Robinson E, Salley A, Beaupre P, Caldwell D, Baucom D, 
Haythornthwaite J: Pain coping strategies that predict patients' and spouses' ratings of 
patients' self-efficacy. Pain 1997, 73:191-199. 
46.  Resnick B: Managing arthritis with exercise. Geriatr Nurs 2001, 22:143-150. 
47.  Westby MD: A health professional's guide to exercise prescription for people with 
arthritis: a review of aerobic fitness activities. Arthritis Care Res 2001, 45:501-511. 
48.  Marks R, Allegrante JP: Chronic osteoarthritis and adherence to exercise: a review of the 
literature. J Aging Phys Act 2005, 13:434-460. 
49.  Field A. Discovering Statistics Using SPSS. 2nd edition. London: SAGE Publications; 2005. 
50. Cohen J: Statistical Power Analysis for the Behavioural Sciences. 2nd edition. Hillsdale, NJ: 
Lawrence Earlbaum Associates; 1988. 
51. Allison PD: Missing data. Thousand Oaks, CA: Sage Publications; 2001.  
52.  Herrero-Beaumont G, Ivorra JA, del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola 
E, Paulino J, Marenco JL, Porto A, Laffon A, Araújo D, Figueroa M, Branco J: 
Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, 
double-blind, placebo-controlled study using acetaminophen as a side comparator. 
Arthritis Rheum 2007, 56:555-567. 
53. Messier SP, Mihalko S, Loeser RF, Legault C, Jolla J, Pfruender J, Prosser B, Adrian A, 
Williamson JD: Glucosamine/chrondroitin combined with exercise for the treatment of 
knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage 2007, 15:1256-1266. 
 34
54.  Evcik D, Sonel B: Effectiveness of a home-based exercise therapy and walking program 
on osteoarthritis of the knee. Rheumatol Int 2002, 22:103-106. 
55.  Talbot LA, Gaines JM, Huynh TN, Metter EJ: A home-based pedometer-driven walking 
program to increase physical activity in older adults with osteoarthritis of the knee: a 
preliminary study. J Am Geriatr Soc 2003, 51:387-392. 
56. Bischoff HA, Roos EM: Effectiveness and safety of strengthening, aerobic, and 
coordination exercises for patients with osteoarthritis. Current Opinion Rheum 2003, 
15:141-144. 
57.  Rejeski WJ, Ettinger WH, Martin K, Morgan T: Treating disability in knee osteoarthritis 
with exercise therapy: a central role for self-efficacy and pain. Arthritis Care Res 1998, 
11:94-101. 
58.  Rejeski WJ, Craven T, Ettinger WH, McFarlane M, Shumaker S: Self-efficacy and pain in 
disability with osteoarthritis of the knee. J Gerontol Series B 1996, 51:24-29. 
59. Rejeski WJ, Miller ME, Foy C, Messier SP, Rapp S: Self-efficacy and the progression of 
functional limitations and self-reported disability in older adults with knee pain. J 
Gerontol Series B 2001, 56:261-265. 
60.  VanBaar ME, Assendelft WJ, Dekker J, Oostendorp RA, Bijlsma, JW: Effectiveness of 
exercise therapy in patients with osteoarthritis of the hip or knee. A systematic review 
of randomized clinical trials. Arthritis Rheum 1999, 42:1361-1369. 
61.  Sharkey NA, Williams NI, Guerin JB: The role of exercise in the prevention and 
treatment of osteoporosis and osteoarthritis. Nurs Clin North Am 2000, 35:209-221. 
62.  Fransen M, McConnell S, Bell M: Therapeutic exercise for people with osteoarthritis of 
the hip or knee. A systemic review. J Rheumatol 2002, 29:1737-1745. 
 35
63.  Schoo AM, Morris ME: Physical Activity and Exercise in People with Osteoarthritis: 
Optimizing Physical Activity and Exercise in Older People. 3rd edition. Oxford: Butterworth 
Heinemann; 2004: 213-227. 
 36
Table 1. Stepping Out program topics and the theoretical constructs addressed by each one 
Mode  
of deliverya 
Topic Content Constructs 
addressed 
Walking guide; 
one-on-one 
consultations 
Provide opportunities 
and social support; 
correct misperceptions 
Provide tips on finding opportunities in 
the environment for walking;  
Discuss barriers to doing the program 
and ways to overcome them in the 
future; 
Discuss walking as an activity readily 
available (e.g., can walk anyway, 
inexpensive); 
Suggest that friends or family be asked 
to provide encouragement and support 
for doing the program. 
Environment 
Walking guide; 
one-on-one 
consultations 
Provide opportunities 
for experiencing 
benefits and learning 
what to expect from 
changing behaviour 
Address health benefits of walking and 
other physical activities for OA 
sufferers; 
Explain normal bodily responses to 
starting a walking program; 
Provide warning signs of excessive 
exercise. 
Outcome 
expectations 
Walking guide Rewarding for 
behaviour change 
 
Discuss positive impact of walking on 
OA symptoms; 
Describe physiological benefits of 
walking as rewards for increasing 
walking behaviour.  
Reinforcement 
Walking guide; 
one-one-one 
consultations 
Behavioural capability  
Mastery learning  
Observational learning 
 
Discuss and demonstrate proper walking 
techniques pertaining to posture, arm 
motion, taking a step, walking stride, 
and pace; 
Discuss ‘safe’ walking; 
Advice on selecting walking shoes; 
Discuss the use of short bouts (1500 
Self-efficacy 
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steps) of walking to improve health and 
OA symptoms; 
Instruct to increase steps at own rate; 
Display stretching exercises. 
Walking guide; 
pedometer;  
log sheets;  
weekly planners; 
one-one 
consultations 
Self-regulation and 
self-monitoring 
 
Provide use of a pedometer for 12 
weeks; 
Advice on and review of setting step 
goals; 
Guide in writing weekly step goals on 
log sheet and request a copy be sent to 
researchers weekly; 
Guide in monitoring step counts of each 
program walk with log sheet and request 
a copy be sent to researchers weekly. 
Guide in planning walks (specifying 
time, place and steps to walk) using a 
weekly planner. 
Self-control 
Walking guide; 
one-on-one 
consultations 
Self-talk Provide techniques for replacing 
negative self-statements with positive 
ones. 
Emotional-coping 
responses 
aThe Walking Guide was a 27-page booklet developed for the Stepping Out program. The 
Walking Guide, a pedometer, log books, and weekly planners were distributed at the Week 6 
session. One-on-one consultations occurred immediately following the assessments at Weeks 6, 
12, and 24. 
OA = osteoarthritis.
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Table 2. Baseline demographic characteristics of participants who completed the study  
 
3-day walking 
group 
5-day walking 
group Total 
 n = 13 n = 15 n = 28 
  n (%) n (%) n (%) 
Sex    
Men 6 (46) 5 (33) 11 (39) 
Women 7 (54) 10 (67) 17 (61) 
Age (years)    
40-59 4 (31) 7 (47) 11 (39) 
60-75 9 (69) 8 (53) 17 (61) 
BMI (kg/m2)    
<25 3 (23) 3 (20) 6 (21) 
>25 10 (77) 12 (80) 22 (79) 
Marital status    
Married or common-law relationship 9 (69) 9 (60) 18 (64) 
Single 4 (31) 6 (40) 10 (36) 
Highest educational level achieved    
High school degree or less 5 (39) 6 (40) 11 (39) 
Schooling beyond high school 8 (61) 9 (60) 17 (61) 
Current employment status    
Employed 7 (54) 6 (40) 13 (46) 
Not employed 6 (46) 9 (60) 15 (54) 
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Main lifetime occupation     
Manager or professional 8 (61) 4 (27) 12 (43) 
Other 5 (39) 11 (73) 16 (57) 
Note: No significant differences were found between groups for any demographic variable 
(P>0.05). BMI = body mass index. 
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Table 3. Median scores and interquartile ranges for the main study outcomes  
 
 Week 
 0 6 12 18 24 6-24 
Physical activity 
(min/week) 
25th 20.00 30.00 150.00 197.50 120.00 z  2.88 
Median 55.00 100.00a 225.00b 352.50c 190.00d P <0.001 
75th 108.75 221.25 360.00 555.00 405.00 r  0.38 
Physical function  
Self-paced step test 
(seconds) 
25th 92.50 75.00 68.25 60.50 58.50 z  -4.62 
Median 104.00 90.50a 79.50b 73.50c 70.00d P <0.001 
75th 129.75 102.50 90.25 81.50 75.75 r  0.62 
WOMAC measures 
Arthritis pain  
25th 11.00 8.00 5.00 5.25 3.25 z  -2.61 
Median 15.50 15.00 12.50b 12.00 9.00 P 0.01 
75th 24.75 24.75 19.00 19.00 14.00 r  0.35 
Stiffness  
25th 7.25 3.50 3.25 4.00 3.25 z  -1.87 
Median 10.00 7.00a 7.00 5.50 5.00 P 0.06 
75th 14.00 12.00 11.00 10.75 9.50 r  0.25 
Physical function  
25th 44.25 26.50 13.00 12.00 15.75 z  -3.11 
Median 63.50 58.00a 36.50b 33.00 35.00 P <0.001 
75th 86.50 78.25 80.50 60.50 57.00 r  0.42 
Pain after step test 
25th 9.25 6.25 1.50 1.88 0.25 z  -3.11 
Median 15.00 11.50 7.50b 8.50 4.50 P <0.001 
75th 24.75 22.00 16.00 15.00 13.25 r  0.42 
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Total index 
25th 61.50 36.50 29.00 23.13 23.50 z  -2.95 
Median 89.50 77.50a 53.00b 48.00 51.50 P <0.001 
75th 123.75 119.00 111.50 85.25 80.00 r  0.39 
Note. Z scores, P-values and effect sizes (r) for changes between Weeks 6 and 24 are shown in 
the right hand column. 
a Week 6 significantly different from Week 0. 
b Week 12 significantly different from Week 6. 
c Week 18 significantly different from Week 12. 
d Week 24 significantly different from Week 18. 
r = Effect size; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index. 
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Table 4. Median scores, interquartile range for secondary outcome variables  
 
 Week 
 0 6 12 18 24  6-24 
Arthritis self-efficacy measures 
Pain  
25th 45.00 53.50  58.50 60.50 70.00 z  2.64
Median 55.00 69.00 a 72.00 71.00 80.00d P 0.01
75th 72.00 75.50 86.00 90.00 91.50 r  0.35
Function  
25th 58.89 68.61 72.50 74.17 73.61 z  1.91
Median 74.44 79.44 86.67 88.33 88.89 P 0.06
75th 89.44 89.72 94.72 92.22 94.17 r  0.26
Other symptoms  
25th 43.75 57.08 70.42 73.33 78.75 z  -2.96
Median 61.67 68.33a 78.33b 83.33 85.83d P <0.001
75th 80.00 86.25 87.92 89.58 90.00 r  0.40
Corrdelates of physical activity measures 
Self-regulation 
25th 23.25 19.50 34.00 33.38 30.75 z  3.69
Median 30.00 27.00 38.00b 39.00 39.00 P <0.001
75th 34.00 36.50 45.00 48.25 47.25 r  0.49
Self-efficacy 
25th 2.40 2.40 2.65 2.80 2.45 z  1.79
Median 2.80 3.00 3.10b 3.20 3.30 P 0.07
75th 3.20 3.35 3.55 3.60 3.75 r  0.24
Benefits 
25th 53.00 53.25 54.25 53.00 53.00 z  -0.69
Median 56.00 56.00 57.00 56.00 54.50 P 0.49
75th 62.50 63.00 65.00 64.00 64.25 r  0.09
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Barriers 
25th 0.87 0.78 0.62 0.48 0.48 z  -2.57
Median 1.48 1.04a 1.02 0.86 0.98 P 0.01
75th 2.03 1.63 1.46 1.55 1.47 r  0.34
Anxiety and depression 
(Goldberg) 
25th 4.25 1.25 2.00 2.00 1.00 z  -1.73
Median 6.00 5.00 4.00 5.00 3.00 P 0.08
75th 8.75 7.75 5.75 6.00 5.75 r  0.23
Weight (kg) 
25th 69.25 69.88 72.00 69.38 69.00 z  -1.57
Median 79.50 80.00 81.00 b 79.25 c 79.50 d P 0.11
75th 95.50 97.00 94.00 89.13 91.75 r  0.21
Note. Z scores, P-values and effect sizes (r) for changes between Weeks 6 and 24 are shown in 
the right hand column. 
a Week 6 significantly different from Week 0. 
b Week 12 significantly different from Week 6. 
d Week 24 significantly different from Week 18. 
r = Effect size. 
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Figure legends 
 
Figure 1. Study design. GS = glucosamine sulphate.  
 
Figure 2. Process of recruitment for the study. OA, osteoarthritis. [AU: Please define PA] PA 
= physical activity. 
 
Figure 3.Compliance with the Stepping Out program. (a) The percentage of participants who 
complied with the number of ‘walking’ days per week of the walking program (Weeks 7 to 18 of 
the study). (b) Mean number of steps walked each ‘walking’ day during the 12-week Stepping 
Out program (Weeks 7 to 18 of the study). 
